2024
Intravenous infusion of auto-serum-expanded autologous mesenchymal stem cells into chronic severe brain injury patients
Yamaki T, Oka S, Iyama S, Sasaki M, Onodera R, Kataoka-Sasaki Y, Namioka T, Namioka A, Nakazaki M, Takemura M, Ukai R, Yokoyama T, Sasaki Y, Yamashita T, Kobayashi M, Yamaguchi M, Fukino M, Takazawa T, Hayasaka M, Owaku T, Funakura M, Onodera S, Ito Y, Kobune M, Kato J, Ishiai S, Kocsis J, Odaki M, Iwadate Y, Kobayashi S, Honmou O. Intravenous infusion of auto-serum-expanded autologous mesenchymal stem cells into chronic severe brain injury patients. Interdisciplinary Neurosurgery 2024, 36: 101927. DOI: 10.1016/j.inat.2023.101927.Peer-Reviewed Original ResearchSevere brain injury patientsAutologous mesenchymal stem cellsBrain injury patientsIntravenous infusionMesenchymal stem cellsAdverse eventsInjury patientsInfused mesenchymal stem cellsHealth Stroke ScaleSerious adverse eventsFugl-Meyer AssessmentInitial case seriesBrain metabolic activityStem cellsMSC infusionStroke ScaleNeurological deteriorationBarthel IndexCase seriesCNS tumorsNeurological functionFunctional statusFunctional improvementChronic patientsPlacebo effect
2021
Intravenous infusion of auto serum-expanded autologous mesenchymal stem cells in spinal cord injury patients: 13 case series
Honmou O, Yamashita T, Morita T, Oshigiri T, Hirota R, Iyama S, Kato J, Sasaki Y, Ishiai S, Ito YM, Namioka A, Namioka T, Nakazaki M, Kataoka-Sasaki Y, Onodera R, Oka S, Sasaki M, Waxman SG, Kocsis JD. Intravenous infusion of auto serum-expanded autologous mesenchymal stem cells in spinal cord injury patients: 13 case series. Clinical Neurology And Neurosurgery 2021, 203: 106565. PMID: 33667953, DOI: 10.1016/j.clineuro.2021.106565.Peer-Reviewed Original ResearchConceptsSpinal cord injuryAmerican Spinal Injury Association Impairment ScaleMSC infusionAutologous mesenchymal stem cellsASIA CASIA DIntravenous infusionMesenchymal stem cellsSCI patientsFunctional statusFunctional improvementSpinal cord injury patientsSpinal Cord Independence MeasureASIA B patientsASIA C patientsPhase 2 studySerious adverse eventsCord injury patientsCurrent therapeutic optionsStem cellsASIA BASIA gradeC patientsNeurologic improvementAdverse events